Li H. Bian

No. 8 Dongda Street
Beijing, 100071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis.

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis.

Journal: Cancer medicine

Published: June 06, 2026

Protocol and statistical designs in classic clinical research-toripalimab series trial analysis.

Protocol and statistical designs in classic clinical research-toripalimab series trial analysis.

Journal: Cancer biology & medicine

Published: April 13, 2026

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Journal: Cancer medicine

Published: November 08, 2025

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial.

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial.

Journal: Nature communications

Published: August 29, 2025

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: June 21, 2025

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Journal: Cancer medicine

Published: June 02, 2025

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Journal: International journal of clinical oncology

Published: May 05, 2025

Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses.

Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: March 24, 2025

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.

Journal: Scientific reports

Published: January 30, 2025

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China.

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China.

Journal: World journal of surgical oncology

Published: March 02, 2024

Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.

Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.

Journal: The oncologist

Published: January 29, 2024

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.

Journal: Heliyon

Published: October 23, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026